Approximately one in four commercial motor vehicle (CMV) drivers in the U.S. are estimated to possess mild or higher levels of obstructive sleep apnea (OSA), the most common sleep-breathing disorder that is associated with significant medical consequences (including cardiovascular disease and diabetes). A major symptom of sleep apnea is excessive daytime sleepiness, which is highly correlated to impaired driving performance and may result in an increased risk of being in traffic--or work-related incidents. The most prescribed and cost-effective first-line treatment for OSA is nasal continuous positive airway pressure (CPAP). Two leading U.S. carriers partnered with commercial sleep apnea providers to implement obstructive sleep apnea (OSA) programs that screen, diagnose, treat, and manage their OSA-positive CMV drivers. This case study provides an overview of these OSA programs; outlines each carrier's screening, testing, and compliance protocols; and compares and contrasts their approaches. Focus group research was also conducted with drivers and staff involved in each program to assess their perceptions and opinions of their respective OSA programs. While the majority of drivers expressed overall satisfaction participating in their carrier's OSA program, both drivers and staff stressed the difficulty of healthy eating, exercise, and weight loss as adjunct OSA treatments. Finally, staff expressed the importance of coordination between the carrier and the OSA provider to provide driver support.